Cargando…
Role of Comorbidities in Optimizing Decision-Making for Allogeneic Hematopoietic Cell Transplantation
Allogeneic conventional hematopoietic cell transplantation (HCT) following high-dose, myeloablative conditioning regimens has been used since the 1970’s as potentially curative treatment for patients with malignant, hematological disorders. The toxicities of conditioning regimens have limited conven...
Autores principales: | Sorror, Mohamed L., Storb, Rainer F. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Università Cattolica del Sacro Cuore
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2997746/ https://www.ncbi.nlm.nih.gov/pubmed/21152378 http://dx.doi.org/10.4084/MJHID.2010.015 |
Ejemplares similares
-
What Role Is There for Antithymocyte Globulin in Allogeneic Nonmyeloablative Canine Hematopoietic Cell Transplantation?
por: Diaconescu, Razvan, et al.
Publicado: (2005) -
Comparison of Minimal Residual Disease as Outcome Predictor for AML Patients in First Complete Remission Undergoing Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation
por: Walter, Roland B., et al.
Publicado: (2014) -
Pre-transplant expressions of microRNAs, comorbidities, and post-transplant mortality
por: Sorror, Mohamed L., et al.
Publicado: (2018) -
History of hematopoietic cell transplantation: challenges and progress
por: Granot, Noa, et al.
Publicado: (2020) -
Optimizing allogeneic grafts in hematopoietic stem cell transplantation
por: Xu, Zheng‐Li, et al.
Publicado: (2021)